US generic pricing pressure
US generics declined due to additional competition and pricing pressure, which may continue.
medium · management_commentary
Sunpharma Ltd — Q4 FY25
Sun Pharma reported Q4 FY25 consolidated revenue of INR 12,816 crore, up 8.5% YoY, with EBITDA of INR 3,716 crore (+22.4% YoY) and margin expansion of 340 bps to 28.7%.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
MFN/tariff policy uncertainty
Lack of clarity on MFN and tariff policies could impact US specialty pricing and access.
high · analyst_questionLeqselvi patent litigation risk
Leqselvi launch may be at risk due to ongoing patent litigation; potential damages if lost.
high · analyst_questionTax rate increase
Effective tax rate rose to 19.8% in Q4 from 5.1% last year, expected to inch up further.
medium · data_observation